The burgeoning popularity of tirzepatide , initially for diabetes , is creating significant interest within the UK , prompting a notable shift in peptide trends. Availability these treatments remains a complex challenge , with National Health Service coverage currently limited and independent providers offering treatment at a premium . Questions ar